Immuneering Corporation announced on September 10, 2025, its plans to release updated overall survival data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. The data, which will include 9 months median follow-up for 34 patients, is scheduled for release on September 25, 2025.
The company previously reported an exceptional 94% overall survival (OS) observed at 6 months for atebimetinib + mGnP, significantly higher than the 67% OS at 6 months for standard of care gemcitabine/nab-paclitaxel (GnP). Historically, the 6-month OS for standard of care GnP dropped to approximately 47% by 9 months.
Immuneering will also present this updated data at the Pancreatic Cancer Action Network (PanCAN) Annual Scientific Summit on September 28, 2025. Additionally, the company plans to present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit, further highlighting its innovative approach to cancer therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.